APOC3 and hypertriglyceridemia: By targeting the 3ʹ UTR of apolipoprotein C3 mRNA, volanesorsen reduces the levels of triglycerides and apolipoprotein C3, which represent two known risk factors for cardiovascular disease, while increasing the levels of low‐density and high‐density lipoprotein cholesterol and apolipoprotein B in patients with FCS and hypertriglyceridemia (Graham et al,2013; EMA, 2019).